<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995006</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 264/13</org_study_id>
    <nct_id>NCT01995006</nct_id>
  </id_info>
  <brief_title>Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects</brief_title>
  <official_title>Effect of Metamizole on Renal Function in Salt-depleted Healthy Subjects Single-center, Randomized, Open, Controlled Parallel-group Study to Investigate the Effects of Oral Metamizole or Naproxen on Renal Function in Healthy Male Salt-depleted Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned study is a single-center, randomized, open-label parallel group study in 16&#xD;
      healthy male subjects. Study subjects will be randomly allocated either to the metamizole&#xD;
      group (1) or to the naproxen group (2). All participants will start with a low sodium diet&#xD;
      (approximately 50 mmol Na+ per day) 7 days before the first drug intake and maintain the diet&#xD;
      until the end of the study (14 days in total). Salt-depletion is an accepted model to enhance&#xD;
      production of vasodilatory prostaglandins and to increase renal sensitivity to prostaglandin&#xD;
      inhibition. On the first day of treatment (Day 1), a single dose of metamizole or naproxen&#xD;
      will be administered to investigate the effects after a single dose and to collect single&#xD;
      dose pharmacokinetic profiles. Starting on Day 2, all participants will receive therapeutic&#xD;
      doses, i.e. 1000 mg metamizole 'ter in die' (TID, three times a day) or 500 mg naproxen 'bis&#xD;
      in die' (BID, twice a day) for one week and on Day 7 pharmacokinetics and pharmacodynamics&#xD;
      effects will be assessed under near steady-state conditions.&#xD;
&#xD;
      The primary objective is the characterization of the renal effects of metamizole by&#xD;
      determination of the glomerular filtration rate (GFR) using the inulin clearance. Secondary&#xD;
      objectives are the characterization of the urinary excretion of prostaglandin E2 (PGE2) and&#xD;
      the prostaglandin I2 (PGI2) metabolite 6-keto-prostaglandin F1 (PGF1)alpha as well as the&#xD;
      urinary excretion of sodium and potassium.&#xD;
&#xD;
      Overall, clinical experience suggests better renal tolerability of metamizole possibly due to&#xD;
      less potent COX-inhibition compared to classical nonsteroidal antiinflammatory drugs&#xD;
      (NSAIDs). If this could be confirmed, metamizole would be a valuable alternative for&#xD;
      treatment of painful conditions in patients with impaired renal function. Therefore, the aim&#xD;
      of this study is to examine the effects of metamizole on renal function in comparison with&#xD;
      the non-specific COX-inhibitor naproxen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the urinary excretion of the prostaglandin E2 (PGE2) and of the prostacyclin (PGI2) metabolite 6-keto-PGF1alpha</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of urine levels of sodium, potassium and creatinine and the urinary output</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters of each drug will be derived either directly from observed data or by analysis of the concentration-time profiles</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>The maximum plasma concentration (Cmax) and time to reach Cmax (tmax)&#xD;
The terminal elimination rate constant with the respective half-life (t½)&#xD;
The area under the plasma concentration-time curve from zero to different time points (AUC0-24, AUC0-∞)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metamizole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metamizole 1000mg TID Day 1 till Day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 500 mg BID Day 1 till Day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metamizole</intervention_name>
    <description>metamizol tablets (500mg): 1000mg TID during 7 days</description>
    <arm_group_label>Metamizole</arm_group_label>
    <other_name>dipyrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen tablets (500mg): 500 mg BID during 7 days</description>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>Naproxen sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects aged between 18 and 45 years (inclusive) at screening&#xD;
&#xD;
          -  BMI between 18 and 28 kg/m2 (inclusive) and body weight at least 50 kg at screening.&#xD;
&#xD;
          -  systolic blood pressure (SBP): 100-140 mmHg, diastolic blood pressure (DBP): 60-90&#xD;
             mmHg and heart rate (HR): 45-90 bpm (inclusive), measured on the leading arm*, in the&#xD;
             supine position at screening.&#xD;
&#xD;
          -  No clinically significant findings on the physical examination at screening.&#xD;
&#xD;
          -  12-lead ECG without clinically relevant abnormalities at screening.&#xD;
&#xD;
          -  Signed informed consent prior to any study-mandated procedure.&#xD;
&#xD;
          -  Hematology and clinical chemistry results not deviating from the normal range to a&#xD;
             clinically relevant extent at screening.&#xD;
&#xD;
          -  Ability to communicate well with the investigator and to understand and comply with&#xD;
             the requirements of the study.&#xD;
&#xD;
               -  leading arm right = writing with right hand&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking &gt; 5 cigarettes per day.&#xD;
&#xD;
          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period&#xD;
             prior to screening.&#xD;
&#xD;
          -  Loss of ≥ 250 ml of blood within 3 months prior to screening.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days prior to screening.&#xD;
&#xD;
          -  Previous treatment with any prescribed or over-the-counter (OTC) medication (including&#xD;
             herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of&#xD;
             the study.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
&#xD;
          -  Positive results from urine drug screen at screening.&#xD;
&#xD;
          -  History or clinical evidence of any disease (e.g. GIT-disease: Morbus Crohn, Colitis&#xD;
             Ulcerosa, anamnestic gastrointestinal bleeding) and/or existence of any surgical or&#xD;
             medical condition, which might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the study drugs, or which might increase the risk for toxicity.&#xD;
&#xD;
          -  Known hypersensitivity to Aspirin or other NSAIDs or any excipients of the drug&#xD;
             formulations.&#xD;
&#xD;
          -  Known food allergy, which make the adherence to the diet impossible&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Haschke, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Research Unit, University Hospital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effect</keyword>
  <keyword>metamizole</keyword>
  <keyword>salt-depleted</keyword>
  <keyword>subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

